{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,3]],"date-time":"2026-08-03T05:19:21Z","timestamp":1785734361346,"version":"3.56.0"},"reference-count":44,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2023,12,1]],"date-time":"2023-12-01T00:00:00Z","timestamp":1701388800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,12,1]],"date-time":"2023-12-01T00:00:00Z","timestamp":1701388800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2023,11,14]],"date-time":"2023-11-14T00:00:00Z","timestamp":1699920000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100004325","name":"AstraZeneca","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004325","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","lungcancerjournal.info","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Lung Cancer"],"published-print":{"date-parts":[[2023,12]]},"DOI":"10.1016\/j.lungcan.2023.107422","type":"journal-article","created":{"date-parts":[[2023,11,11]],"date-time":"2023-11-11T11:34:53Z","timestamp":1699702493000},"page":"107422","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":13,"special_numbering":"C","title":["Patient-reported outcomes with durvalumab, with or without tremelimumab, plus chemotherapy as first-line treatment for metastatic non-small-cell lung cancer (POSEIDON)"],"prefix":"10.1016","volume":"186","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-7077-8801","authenticated-orcid":false,"given":"Edward B.","family":"Garon","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Byoung Chul","family":"Cho","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alexander","family":"Luft","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jorge","family":"Alatorre-Alexander","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sarayut Lucien","family":"Geater","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sang-We","family":"Kim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Grygorii","family":"Ursol","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maen","family":"Hussein","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Farah Louise","family":"Lim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cheng-Ta","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Luiz Henrique","family":"Araujo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Haruhiro","family":"Saito","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Niels","family":"Reinmuth","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nenad","family":"Medic","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Helen","family":"Mann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaojin","family":"Shi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Solange","family":"Peters","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tony","family":"Mok","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Melissa","family":"Johnson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.lungcan.2023.107422_b0005","doi-asserted-by":"crossref","first-page":"1663","DOI":"10.1038\/s41416-022-01743-4","article-title":"Biomarkers of response to PD-1 pathway blockade","volume":"126","author":"Li","year":"2022","journal-title":"Br. J. Cancer"},{"key":"10.1016\/j.lungcan.2023.107422_b0010","first-page":"1052","article-title":"Identification and characterization of MEDI4736, an antagonistic anti-PD-L1 monoclonal antibody, Cancer","volume":"3","author":"Stewart","year":"2015","journal-title":"Immunol. Res."},{"key":"10.1016\/j.lungcan.2023.107422_b0015","doi-asserted-by":"crossref","first-page":"1583","DOI":"10.1517\/14712598.8.10.1583","article-title":"Tremelimumab (CP-675,206): a fully human anticytotoxic T lymphocyte-associated antigen 4 monoclonal antibody for treatment of patients with advanced cancers","volume":"8","author":"Tarhini","year":"2008","journal-title":"Expert Opin. Biol. Ther."},{"key":"10.1016\/j.lungcan.2023.107422_b0020","doi-asserted-by":"crossref","first-page":"1213","DOI":"10.1200\/JCO.22.00975","article-title":"for the POSEIDON investigators, Durvalumab with or without tremelimumab in combination with chemotherapy as first-line therapy for metastatic non\u2013small-cell lung cancer: the phase III POSEIDON study","volume":"41","author":"Johnson","year":"2023","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.lungcan.2023.107422_b0025","unstructured":"IMFINZI (durvalumab) prescribing information, 2022. https:\/\/den8dhaj6zs0e.cloudfront.net\/50fd68b9-106b-4550-b5d0-12b045f8b184\/9496217c-08b3-432b-ab4f-538d795820bd\/9496217c-08b3-432b-ab4f-538d795820bd_viewable_rendition__v.pdf. Accessed February 27, 2023."},{"key":"10.1016\/j.lungcan.2023.107422_b0030","unstructured":"AstraZeneca, Press release, 2022. https:\/\/www.astrazeneca.com\/media-centre\/press-releases\/2022\/imfinzi-imjudo-approved-in-japan-for-3-cancers.html. Accessed February 27, 2023."},{"key":"10.1016\/j.lungcan.2023.107422_b0035","unstructured":"AstraZeneca press release, 2023. https:\/\/www.astrazeneca.com\/media-centre\/press-releases\/2023\/imfinzi-plus-imjudo-approved-in-the-eu-for-patients-with-advanced-liver-and-non-small-cell-lung-cancers.html. Accessed February 27, 2023."},{"key":"10.1016\/j.lungcan.2023.107422_b0040","doi-asserted-by":"crossref","first-page":"288","DOI":"10.1016\/j.lungcan.2013.03.008","article-title":"Symptom burden and quality of life in advanced non-small cell lung cancer patients in France and Germany","volume":"81","author":"Iyer","year":"2013","journal-title":"Lung Cancer"},{"key":"10.1016\/j.lungcan.2023.107422_b0045","first-page":"181","article-title":"The symptom burden of non-small cell lung cancer in the USA: a real-world cross-sectional study","volume":"22","author":"Iyer","year":"2014","journal-title":"Support Care Cancer"},{"key":"10.1016\/j.lungcan.2023.107422_b0050","first-page":"331","article-title":"Clinical management of pain in advanced lung cancer, Clin Med Insights","volume":"6","author":"Simmons","year":"2012","journal-title":"Oncol."},{"key":"10.1016\/j.lungcan.2023.107422_b0055","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1080\/J354v21n04_14","article-title":"Role of corticosteroids in palliative care","volume":"21","author":"Shih","year":"2007","journal-title":"J. Pain Palliat. Care Pharmacother."},{"key":"10.1016\/j.lungcan.2023.107422_b0060","doi-asserted-by":"crossref","first-page":"834","DOI":"10.1089\/jpm.2011.0260","article-title":"Dyspnea in palliative care: expanding the role of corticosteroids","volume":"15","author":"Lin","year":"2012","journal-title":"J. Palliat. Med."},{"key":"10.1016\/j.lungcan.2023.107422_b0065","doi-asserted-by":"crossref","first-page":"370","DOI":"10.1016\/j.jpainsymman.2006.12.005","article-title":"The impact of symptoms, coping capacity, and social support on quality of life experience over time in patients with lung cancer","volume":"34","author":"Henoch","year":"2007","journal-title":"J. Pain Symptom Manage."},{"key":"10.1016\/j.lungcan.2023.107422_b0070","first-page":"4123","article-title":"Symptom assessment for patients with non-small cell lung cancer scheduled for chemotherapy","volume":"36","author":"Silvoniemi","year":"2016","journal-title":"Anticancer Res."},{"key":"10.1016\/j.lungcan.2023.107422_b0075","doi-asserted-by":"crossref","first-page":"497","DOI":"10.1016\/j.cllc.2017.02.008","article-title":"Emotional problems, quality of life, and symptom burden in patients with lung cancer","volume":"18","author":"Morrison","year":"2017","journal-title":"Clin. Lung Cancer"},{"key":"10.1016\/j.lungcan.2023.107422_b0080","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1188\/11.ONF.23-31","article-title":"Determinants of quality of life in patients near the end of life: a longitudinal perspective","volume":"38","author":"Hermann","year":"2011","journal-title":"Oncol. Nurs. Forum"},{"key":"10.1016\/j.lungcan.2023.107422_b0085","doi-asserted-by":"crossref","first-page":"301","DOI":"10.1016\/j.cllc.2021.02.010","article-title":"Patient-reported outcomes with durvalumab with or without tremelimumab versus standard chemotherapy as first-line treatment of metastatic non-small-cell lung cancer (MYSTIC)","volume":"22","author":"Garon","year":"2021","journal-title":"Clin. Lung Cancer"},{"key":"10.1016\/j.lungcan.2023.107422_b0090","doi-asserted-by":"crossref","first-page":"174","DOI":"10.1016\/j.ejca.2023.01.015","article-title":"First-line nivolumab plus ipilimumab with two cycles of chemotherapy versus chemotherapy alone (four cycles) in metastatic non-small cell lung cancer: CheckMate 9LA 2-year patient-reported outcomes","volume":"183","author":"Reck","year":"2023","journal-title":"Eur. J. Cancer"},{"key":"10.1016\/j.lungcan.2023.107422_b0095","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1016\/j.ejca.2019.05.008","article-title":"Nivolumab plus ipilimumab versus chemotherapy as first-line treatment in advanced non-small-cell lung cancer with high tumour mutational burden: patient-reported outcomes results from the randomised, open-label, phase III CheckMate 227 trial","volume":"116","author":"Reck","year":"2019","journal-title":"Eur. J. Cancer"},{"key":"10.1016\/j.lungcan.2023.107422_b0100","doi-asserted-by":"crossref","first-page":"387","DOI":"10.1016\/S1470-2045(19)30801-0","volume":"21","author":"Garassino","year":"2020","journal-title":"Lancet Oncol."},{"key":"10.1016\/j.lungcan.2023.107422_b0105","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1200\/JCO.19.01348","article-title":"Health-related quality of life with carboplatin-paclitaxel or nab-paclitaxel with or without pembrolizumab in patients with metastatic squamous non-small-cell lung cancer","volume":"38","author":"Mazieres","year":"2020","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.lungcan.2023.107422_b0110","doi-asserted-by":"crossref","first-page":"1600","DOI":"10.1016\/S1470-2045(17)30690-3","article-title":"Health-related quality-of-life results for pembrolizumab versus chemotherapy in advanced, PD-L1-positive NSCLC (KEYNOTE-024): a multicentre, international, randomised, open-label phase 3 trial","volume":"18","author":"Brahmer","year":"2017","journal-title":"Lancet Oncol."},{"key":"10.1016\/j.lungcan.2023.107422_b0115","doi-asserted-by":"crossref","first-page":"2530","DOI":"10.1200\/JCO.19.03158","article-title":"Safety and patient-reported outcomes of atezolizumab plus chemotherapy with or without bevacizumab versus bevacizumab plus chemotherapy in non-small-cell lung cancer","volume":"38","author":"Reck","year":"2020","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.lungcan.2023.107422_b0120","doi-asserted-by":"crossref","first-page":"228","DOI":"10.1016\/j.ejca.2008.10.026","article-title":"New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1)","volume":"45","author":"Eisenhauer","year":"2009","journal-title":"Eur. J. Cancer"},{"key":"10.1016\/j.lungcan.2023.107422_b0125","series-title":"IASLC Staging Manual in Thoracic Oncology","author":"Rami-Porta","year":"2016"},{"key":"10.1016\/j.lungcan.2023.107422_b0130","doi-asserted-by":"crossref","first-page":"365","DOI":"10.1093\/jnci\/85.5.365","article-title":"The European Organization for Research and Treatment of Cancer QLQ-C30: a quality-of-life instrument for use in international clinical trials in oncology","volume":"85","author":"Aaronson","year":"1993","journal-title":"J. Natl Cancer Inst."},{"key":"10.1016\/j.lungcan.2023.107422_b0135","doi-asserted-by":"crossref","first-page":"635","DOI":"10.1016\/0959-8049(94)90535-5","article-title":"The EORTC QLQ-LC13: a modular supplement to the EORTC core quality of life questionnaire (qlq-c30) for use in lung cancer clinical trials. eortc study group on quality of life","volume":"30a","author":"Bergman","year":"1994","journal-title":"Eur. J. Cancer"},{"key":"10.1016\/j.lungcan.2023.107422_b0140","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1200\/JCO.1998.16.1.139","article-title":"Interpreting the significance of changes in health-related quality-of-life scores","volume":"16","author":"Osoba","year":"1998","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.lungcan.2023.107422_b0145","unstructured":"N.W. Scott, P.M. Fayers, N.K. Aaronson, A. Bottomley, A. de Graeff, M. Groenvold, C. Gundy, M. Koller, M.A. Petersen, M.A.G. Sprangers, The EORTC Quality of Life Group, EORTC QLQ-C30 reference values manual (2nd edition). Brussels, Belgium: EORTC Quality of Life Group (2008). Available at: https:\/\/www.eortc.org\/app\/uploads\/sites\/2\/2018\/02\/reference_values_manual2008.pdf. Accessed April 26, 2022."},{"key":"10.1016\/j.lungcan.2023.107422_b0150","first-page":"125","article-title":"Payer perspectives on patient-Rreported outcomes in health care decision making: oncology examples","volume":"23","author":"Brogan","year":"2017","journal-title":"J. Manag. Care Spec. Pharm."},{"key":"10.1016\/j.lungcan.2023.107422_b0155","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1007\/s43441-020-00195-3","article-title":"Collection of post-treatment PRO data in oncology clinical trials","volume":"55","author":"Lundy","year":"2021","journal-title":"Ther. Innov. Regul. Sci."},{"key":"10.1016\/j.lungcan.2023.107422_b0160","doi-asserted-by":"crossref","first-page":"337","DOI":"10.3109\/07853890109002087","article-title":"EQ-5D: a measure of health status from the EuroQol Group","volume":"33","author":"Rabin","year":"2001","journal-title":"Ann. Med."},{"key":"10.1016\/j.lungcan.2023.107422_b0165","first-page":"213","article-title":"Quality of life during clinical trials: conceptual model for the Lung Cancer Symptom Scale (LCSS)","volume":"2","author":"Hollen","year":"1994","journal-title":"Support Care Cancer"},{"key":"10.1016\/j.lungcan.2023.107422_b0170","doi-asserted-by":"crossref","first-page":"2087","DOI":"10.1002\/1097-0142(19940415)73:8<2087::AID-CNCR2820730813>3.0.CO;2-X","article-title":"Measurement of quality of life in patients with lung cancer in multicenter trials of new therapies psychometric assessment of the lung cancer symptom scale","volume":"73","author":"Hollen","year":"1994","journal-title":"Cancer"},{"issue":"Suppl 1","key":"10.1016\/j.lungcan.2023.107422_b0175","doi-asserted-by":"crossref","first-page":"S51","DOI":"10.1016\/S0959-8049(05)80262-X","article-title":"Quality of life assessment in individuals with lung cancer: testing the Lung Cancer Symptom Scale (LCSS)","volume":"29A","author":"Hollen","year":"1993","journal-title":"Eur. J. Cancer"},{"key":"10.1016\/j.lungcan.2023.107422_b0180","doi-asserted-by":"crossref","first-page":"140","DOI":"10.1016\/j.lungcan.2017.09.011","article-title":"Patient-reported outcome measures (PROMs) in the management of lung cancer: a systematic review","volume":"113","author":"Bouazza","year":"2017","journal-title":"Lung Cancer"},{"key":"10.1016\/j.lungcan.2023.107422_b0185","first-page":"e2122998","article-title":"Evaluation of technology-enabled monitoring of patient-reported outcomes to detect and treat toxic effects linked to immune checkpoint inhibitors","volume":"4","author":"Msaouel","year":"2021","journal-title":"J. Am. Med. Assoc.Network Open."},{"key":"10.1016\/j.lungcan.2023.107422_b0190","first-page":"e2200161","author":"McKelvey","year":"2023","journal-title":"Study Design to Harmonize Patient-Reported Outcomes across Data Sets"},{"key":"10.1016\/j.lungcan.2023.107422_b0195","first-page":"1360","volume":"127","author":"Voon","year":"2021","journal-title":"Health-Related Quality-of-Life Assessment of Patients with Solid Tumors on Immuno-Oncology Therapies"},{"key":"10.1016\/j.lungcan.2023.107422_b0200","doi-asserted-by":"crossref","DOI":"10.1177\/11769351231178587","article-title":"Development of an eHealth tool for capturing and analyzing the immune-related adverse events (iraes) in cancer treatment","volume":"22","author":"Moradian","year":"2023","journal-title":"Cancer Inform."},{"key":"10.1016\/j.lungcan.2023.107422_b0205","doi-asserted-by":"crossref","first-page":"997","DOI":"10.1016\/j.jpainsymman.2022.02.013","article-title":"Patient-reported outcomes during checkpoint inhibition: insight into symptom burden in daily clinical practice","volume":"63","author":"Koldenhof","year":"2022","journal-title":"J. Pain Symptom Manage."},{"key":"10.1016\/j.lungcan.2023.107422_b0210","doi-asserted-by":"crossref","first-page":"738","DOI":"10.1001\/jamaoncol.2016.3328","article-title":"Trustworthiness of patient-reported outcomes in unblinded cancer clinical trials","volume":"3","author":"Atkinson","year":"2017","journal-title":"JAMA Oncol."},{"key":"10.1016\/j.lungcan.2023.107422_b0215","doi-asserted-by":"crossref","first-page":"e18702","DOI":"10.1200\/JCO.2018.36.15_suppl.e18702","article-title":"Exploring open-label bias in patient-reported outcome (PRO) emotional domain scores in cancer trials","volume":"36","author":"Chakravarti","year":"2018","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.lungcan.2023.107422_b0220","doi-asserted-by":"crossref","first-page":"457","DOI":"10.1001\/jamaoncol.2018.6205","article-title":"Investigating potential bias in patient-reported outcomes in open-label cancer trials","volume":"5","author":"Roydhouse","year":"2019","journal-title":"JAMA Oncol."}],"container-title":["Lung Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0169500223009601?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0169500223009601?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,30]],"date-time":"2025-09-30T13:07:18Z","timestamp":1759237638000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0169500223009601"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,12]]},"references-count":44,"alternative-id":["S0169500223009601"],"URL":"https:\/\/doi.org\/10.1016\/j.lungcan.2023.107422","relation":{},"ISSN":["0169-5002"],"issn-type":[{"value":"0169-5002","type":"print"}],"subject":[],"published":{"date-parts":[[2023,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Patient-reported outcomes with durvalumab, with or without tremelimumab, plus chemotherapy as first-line treatment for metastatic non-small-cell lung cancer (POSEIDON)","name":"articletitle","label":"Article Title"},{"value":"Lung Cancer","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.lungcan.2023.107422","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 The Authors. Published by Elsevier B.V.","name":"copyright","label":"Copyright"}],"article-number":"107422"}}